References
- Aalbers CJ, Tak PP, Vervoordeldonk MJ (2011). Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon. F1000 Med Rep, 3, 17.
- Aguilar LK, Guzik BW, Aguilar-Cordova E (2011). Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem, 112, 1969-77. https://doi.org/10.1002/jcb.23126
- Blank C, Brown I, Peterson AC, et al (2004). PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res, 64, 1140-5. https://doi.org/10.1158/0008-5472.CAN-03-3259
- Borghouts C, Kunz C, Groner B (2005). Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci, 11, 713-26. https://doi.org/10.1002/psc.717
- Cao S, Cripps A, Wei MQ (2010). New strategies for cancer gene therapy: progress and opportunities. Clin Exp Pharmacol Physiol, 37, 108-14. https://doi.org/10.1111/j.1440-1681.2009.05268.x
- Cao Y, Zhang L, Kamimura Y, et al (2011). B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. Cancer Res, 71, 1235-43. https://doi.org/10.1158/0008-5472.CAN-10-2217
- Capece D, Verzella D, Fischietti M, Zazzeroni F, Alesse E (2012). Targeting costimulatory molecules to improve antitumor immunity. J Biomed Biotechnol, 2012, 926321.
- Cross D, Burmester JK (2006). Gene therapy for cancer treatment: past, present and future. Clin Med Res, 4, 218-27. https://doi.org/10.3121/cmr.4.3.218
- Danylesko I, Beider K, Shimoni A, Nagler A (2012). Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol, 2012, 753407
- Dong H, Chen L (2003). B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl), 81, 281-7. https://doi.org/10.1007/s00109-003-0430-2
- Dong H, Strome SE, Salomao DR, et al (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 8, 793-800. https://doi.org/10.1038/nm730
- Dulgerian LR, Garrido VV, Stempin CC, Cerban FM (2011). Programmed death ligand 2 regulates arginase induction and modifies Trypanosoma cruzi survival in macrophages during murine experimental infection. Immunology, 133, 29-40. https://doi.org/10.1111/j.1365-2567.2011.03406.x
- Feng Z, Huang B, Zhang G, Li D, Wang H (2002). Investigation on the effect of peptides mixture from tumor cells inducing anti-tumor specific immune response. Sci China C Life Sci, 45, 361-9. https://doi.org/10.1360/02yc9040
- Flies DB, Sandler BJ, Sznol M, Chen L (2011). Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. Yale J Biol Med, 84, 409-21.
- Freeman GJ, Long AJ, Iwai Y, et al (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192, 1027-34. https://doi.org/10.1084/jem.192.7.1027
- Geng H, Zhang GM, Li D, et al (2006). Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol, 176, 1411-20. https://doi.org/10.4049/jimmunol.176.3.1411
- He L, Zhang G, He Y, et al (2005). Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res, 25, 3309-13.
- He YF, Zhang GM, Wang XH, et al (2004). Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol, 173, 4919-28. https://doi.org/10.4049/jimmunol.173.8.4919
- Hofmeyer KA, Jeon H, Zang X (2011). The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol, 2011, 451694.
- Keswani SG, Balaji S, Le L, et al (2012). Pseudotyped AAV Vector-Mediated Gene Transfer in a Human Fetal Trachea Xenograft Model: Implications for In Utero Gene Therapy for Cystic Fibrosis. PLoS One, 7, e43633. https://doi.org/10.1371/journal.pone.0043633
- Lee SK, Seo SH, Kim BS, et al (2005). IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. J Dermatol Sci, 40, 95-103. https://doi.org/10.1016/j.jdermsci.2005.06.008
- Li C, Bowles DE, van Dyke T, Samulski RJ (2005). Adenoassociated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther, 12, 913-25. https://doi.org/10.1038/sj.cgt.7700876
- Paterson AM, Brown KE, Keir ME, et al (2011). The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol, 187, 1097-105. https://doi.org/10.4049/jimmunol.1003496
- Phan GQ, Yang JC, Sherry RM, et al (2003). Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA, 100, 8372-7. https://doi.org/10.1073/pnas.1533209100
- Ponnazhagan S, Mahendra G, Kumar S, et al (2004). Adenoassociated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res, 64, 1781-7. https://doi.org/10.1158/0008-5472.CAN-03-1786
- Qian C, Drozdzik M, Caselmann WH, Prieto J (2000). The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol, 32, 344-51. https://doi.org/10.1016/S0168-8278(00)80082-3
- Qian C, Prieto J (2004). Gene therapy of cancer: induction of anti-tumor immunity. Cell Mol Immunol, 1, 105-11.
- Qiu H, Liu S, Xie C, Long J, Feng Z (2009). Regulating immunity and inhibiting tumor growth by the recombinant peptide sPD-1-CH50. Anticancer Res, 29, 5089-94.
- Rosenberg SA (2001). Progress in human tumour immunology and immunotherapy. Nature, 411, 380-4. https://doi.org/10.1038/35077246
- Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ (2012). Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol, 2012, 656340.
- Sangro B, Qian C, Schmitz V, Prieto J (2002). Gene therapy of hepatocellular carcinoma and gastrointestinal tumors. Ann N Y Acad Sci, 963, 6-12.
- Streck CJ, Dickson PV, Ng CY, et al (2006). Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther, 13, 99-106. https://doi.org/10.1038/sj.cgt.7700878
- Topfer K, Kempe S, Muller N, et al (2011). Tumor evasion from T cell surveillance. J Biomed Biotechnol, 2011, 918471.
- Wiendl H, Mitsdoerffer M, Hofmeister V, et al (2002). A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol, 168, 4772-80. https://doi.org/10.4049/jimmunol.168.9.4772
- Wong RM, Scotland RR, Lau RL, et al (2007). Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol, 19, 1223-34. https://doi.org/10.1093/intimm/dxm091
- Xiao H, Huang B, Yuan Y, et al (2007). Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin Cancer Res, 13, 1823-30. https://doi.org/10.1158/1078-0432.CCR-06-2154
- Xing YN, Liang HW, Zhao L, Xu HM (2011). The antitumor activity of exogenous and endogenous canstatin on colorectal cancer cells. Asian Pac J Cancer Prev, 12, 2713-6.
- Xu L, Liu Y, He X (2006). Expression and purification of soluble human programmed death-1 in Escherichia coli. Cell Mol Immunol, 3, 139-43
- Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, et al (2012). Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med, 209, 1201-17. https://doi.org/10.1084/jem.20112741
- Youngnak P, Kozono Y, Kozono H, et al (2003). Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun, 307, 672-7. https://doi.org/10.1016/S0006-291X(03)01257-9
- Zacchigna S, Zentilin L, Morini M, et al (2004). AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther, 11, 73-80. https://doi.org/10.1038/sj.cgt.7700657
- Zeng Z, Shi F, Zhou L, et al (2011). Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One, 6, e23621. https://doi.org/10.1371/journal.pone.0023621
Cited by
- IL-12 Regulates B7-H1 Expression in Ovarian Cancer-associated Macrophages by Effects on NF-κB Signalling vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5767
- Effect of TLR4 and B7-H1 on Immune Escape of Urothelial Bladder Cancer and its Clinical Significance vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1321
- Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00563
- Soluble immune checkpoints in cancer: production, function and biological significance vol.6, pp.1, 2018, https://doi.org/10.1186/s40425-018-0449-0
- PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression vol.8, pp.3, 2019, https://doi.org/10.1080/2162402X.2018.1557030